Biogen Reports Q3 2026 Financial Results

Biogen reported third-quarter 2026 adjusted EPS of $2.62, above the FactSet consensus of $1.99, and revenue of $2.80 billion, exceeding the $2.63 billion estimate. The company raised the low end of its fiscal 2026 non-GAAP EPS guidance, setting a range of $12.20 to $13.00. Biogen is placing greater focus on newer drug assets to counter competitive pressure on its established multiple sclerosis franchise.